CRISPR/Cas and base editing machinery can already be delivered via lipid nanoparticles to hepatocytes to delete specific genes (e.g., KLKB1 for hereditary angioedema and PCSK9 for familial hypercholesterolaemia), with promising results in clinical trials [46,47]. The gene discussed is PCSK9; the disease is hereditary angioedema.